Retina

The Simplified Age-Related Eye Disease Study (AREDS) Age-Related Macular Degeneration (AMD) Severity Scale has been shown to be predictive of vision loss.

Triple therapy for age-related macular degeneration (AMD) can stabilize vision and reduce the re-treatment rate in patients who do not respond to initial anti-VEGF therapy.

Two transporters that deliver alternative energy sources to the eye may help delay the retinal damage that occurs in diabetes.

Judah Folkman, MD, the pioneer of angiogenesis research, died on January 15th 2008.

A gene, which also behaves as a cancer precursor, has also been found to play a central role in the coordination of retinal proliferation and eye growth during foetal development.

Novagali Pharma's Investigational New Drug Application (IND) to conduct Phase I clinical trials of its Nova63035, for the treatment of diabetic macular oedema (DME), has been granted by the FDA.

The American Academy of Ophthalmology and the American Society of Retina Specialists (ASRS) are pleased to report that a solution has been found that addresses Genentech's decision to no longer allow compounding pharmacies to purchase Avastin (bevacizumab) directly from authorized wholesale distributors.

Ophthotech, Biogen and PDL BioPharma have entered into an exclusive worldwide licensing agreement for an anti-angiogenesis antibody to treat age-related macular degeneration.

Fovea Pharmaceuticals has received designation as Orphan Medicinal Product from the European Commission for rh-RdCVF, its treatment for retinitis pigmentosa (RP).

A new online database of retinal topography maps has been launched by the Optometrists Association of Australia.

A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye.

23-gauge instruments offer numerous advantages over other instruments, such as less irritation, no induction of astigmatism, shorter operation time and lower costs.

A controversial decision by NICE to limit the use of the anti-VEGF drug Lucentis in treating patients with wet AMD, is being reconsidered.

Take a look at what happened in the Retina field in 2007 and what exciting developments are round the corner in 2008.

Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.

OPKO Health has completed its acquisition of Ophthalmic Technologies Inc. (OTI), a privately owned Canadian company.

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.

Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.

Monocyte chemoattractant protein 1 (MCP-1) seems to be responsible for apoptosis of the photoreceptors in certain visual disorders.

Have a look at the AMD therapies taking the first step along the path to approval.

What therapies have made it to Phase II clinical trials?

Take a look at the therapies that have reached Phase III clinical testing.

Take a look at the therapies that have already reached the market.

What are doctors using off-label to treat their AMD patients?